Synbiotics
Synbiotics has been studied in 104 papers since 2017: 14 trials and 1 observational study in people, 1 in animals, 82 reviews; 54 in the past year. The newest paper, Nov 19, 2026: “Effects of synbiotic supplementation on serum lipids, lipoproteins and blood pressure in kidney transplant recipients with overweight or obesity: a randomised controlled trial”.
Research on it is growing 104% faster than aging research as a whole: 12 papers in the latest year counted
14 new papers in 30 daysSee all 102 papers on synbiotics
At a glance
Synbiotics are linked with lower mortality in a human observational study. Independent labs report reduced inflammation, lower TNF-alpha and increased IL-10 in humans. Reviews describe lower C-reactive protein, but a human trial shows no clear effect; body-weight results also differ.
56 findings in 22 papers from 2017 to 2026, 4 of them since August 2026
Independent labs found the same change in people. 12 independent labs in 7 countries; 3 trials, none about aging.
“As seen in Table, over the 4 months, the mean body weight significantly reduced in the synbiotic group, compared to the placebo group, even after adjusting for weight baseline values and energy intakes of participants (p < 0.001).”
2 of its findings point the other way.
- 12 independent labs in 7 countries
- 2 findings against
- 3 trials, none about aging
- Funders: Tabriz University of Medical Sciences and others
- Human trial14
- Humans1
- Animals1
- In silico1
Studies in people
See all 11 studies of synbiotics in people11 studies gave synbiotics to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
down: Decreases total cholesteroleffect size −0.75 down: Decreases systolic blood pressureeffect size −0.74 no change: Has no effect on HDL cholesterol | Randomized trial12 weeks | 46 peopleKidney transplant recipients with overweight or obesity | The British journal of nutrition, Nov 19, 2026 |
down: Decreases fat massmedian −3.00 kg at T6, p < 0.001 no change: Has no effect on fat-free mass | Trial6 months | 17 peopleWomenmean age 52 ± 2.6 yearsPostmenopausal women; Midlife adults; perimenopausal women with migraine and intestinal dysbiosis | Preprints.org, Sep 16, 2026 |
no change: Has no effect on physical function | Randomized trial12 weeks | 51 peoplemen65–79 yearsCommunity-dwelling men with type 2 diabetes mellitus | European journal of nutrition, Aug 19, 2026 |
| Randomized trial12 weeks | 48 peopleaged 22–73 yearsOverweight or obese kidney transplant recipients in the chronic post-transplant phase | Renal failure, Mar 26, 2026 | |
down: Decreases low-density lipoprotein cholesterol down: Decreases fasting blood sugar down: Decreases alanine aminotransferase | Randomized trial12 weeks | 80 peoplePatient cohorts | European journal of medical research, Jan 30, 2026 |
What did studies of synbiotics find?
37Studies of synbiotics measured 37 outcomes; the most studied are inflammation (4 studies), IL-10 (3) and systolic blood pressure (2).
Inflammation
downin humans4
4 studies
Inflammation
downin humans4
Synbiotics decrease inflammation in overweight or obese kidney transplant recipients on a calorie-restricted diet.
“The reduction in serum hs-CRP in the synbiotic group was statistically significant when compared to the placebo group (p = 0.02; ).”
Human trialin overweight or obese kidney transplant recipients on a calorie-restricted diet12 weeks
Renal failure
Synbiotics decrease inflammation in humans (p = 0.02).
“Serum LBP (p = 0.03), hs-CRP (p = 0.02), ICAM-1 (p = 0.04), and IL-6 (p = 0.02) showed significant reductions in the synbiotic group compared to the placebo group.”
Human trialcapsules12 weeks
Renal failure
Synbiotics decrease inflammation in humans (combined with lifestyle modifications).
“significant improvements in some measures of lipid profile (TC and LDL-C), FBS, liver function (ALT and AST), and liver inflammatory biomarkers (TNF-α and IL-6)”
Human trialcombined with lifestyle modifications12 weeksn = 80
European journal of medical research
Synbiotics decrease inflammation in humans (metabolic syndrome).
“synbiotics may restore microbial balance, improve metabolic homeostasis, and attenuate inflammatory pathways.”
Reviewmetabolic syndrome
Minerva gastroenterology
Synbiotics decrease inflammation in humans (stress-induced inflammation).
“Prebiotics and probiotics, which modulate the gut flora, have been shown to improve mood, reduce stress-induced inflammation, and preserve metabolic balance.”
Reviewstress-induced inflammation
Psychological Health and Slowing Metabolism: The Role of Pre/Probiotics in Aging
Preprints.orgPreprint
IL-10
upin humans3
3 studies
IL-10
upin humans3
Synbiotics increase IL-10 in humans.
“The anti-inflammatory IL-10 was significantly upregulated in both stressed and non-stressed participants.”
Human trial12 weeksn = 32
Foods (Basel, Switzerland)
Synbiotics increase IL-10 in humans (significant only in synbiotic group versus placebo).
“IL-10 was significantly increased only in the S-group”
Human trialsignificant only in synbiotic group versus placebo
Nutritional neuroscience
Synbiotics increase IL-10 in humans (SMD 0.30, 95% CI 0.002 to 0.59).
“Conversely, anti-inflammatory IL-10 significantly increased (SMD: 0.30, 95% CI: 0.002 to 0.59).”
ReviewAt least 3 weeks
BioImpacts : BI
Systolic blood pressure
downin humans2
2 studies
Systolic blood pressure
downin humans2
Synbiotics decrease systolic blood pressure in humans (kidney transplant recipients with overweight or obesity; compared with placebo) (effect size −0.74).
“systolic blood pressure ( P = 0·034; effect size: −0·74) in the synbiotic group compared with the placebo group.”
Human trialkidney transplant recipients with overweight or obesity; compared with placebocapsulestwo capsules daily12 weeksn = 46
The British journal of nutrition
Synbiotics decrease systolic blood pressure in humans (NAFLD; compared with placebo) (Change: -16.07±3.56 mmHg; placebo: -1.55±3.01 mmHg; P=0.01 across groups).
“combined symbiotic and alpha-tocopherol, symbiotic and alpha-tocopherol alone administration, compared with the placebo, resulted in significant decreases in SBP”
Human trialNAFLD; compared with placebo2 × 108 CFU/g8 weeks
EXCLI journal
C-reactive protein
downin humans1no changein humans1
2 studies
C-reactive protein
downin humans1no changein humans1
Synbiotics showed no clear effect on C-reactive protein in humans (between study groups, both groups on a low-calorie diet) (P=0.550 between study groups).
“We did not observe any significant effects of the synbiotic supplementation in hs-CRP, and IL-1β between the study groups (P=0.550, P=0.118 respectively).”
Human trialbetween study groups, both groups on a low-calorie diet10 weeks
EXCLI journal
Synbiotics decrease C-reactive protein in humans (SMD -0.49, 95% CI -0.67 to -0.31).
“Synbiotic supplementation was associated with a reduction in C-reactive protein (CRP) (SMD: -0.49, 95% CI: -0.67 to -0.31)”
ReviewAt least 3 weeksn = 3,725
BioImpacts : BI
Body weight
no changein humans1downin humans1
2 studies
Body weight
no changein humans1downin humans1
Synbiotics showed no clear effect on body weight in humans (combined with lifestyle modifications).
“No significant changes were observed in anthropometric measures either within or between groups during the study period.”
Human trialcombined with lifestyle modifications12 weeksn = 80
European journal of medical research
Synbiotics decrease body weight in humans.
“As seen in Table, over the 4 months, the mean body weight significantly reduced in the synbiotic group, compared to the placebo group, even after adjusting for weight baseline values and energy intakes of participants (p < 0.001).”
Human trial4 monthsn = 96
Nutrition & diabetes
TNF-alpha
downin humans2
2 studies
TNF-alpha
downin humans2
Synbiotics decrease TNF-alpha in humans (between study groups, both groups on a low-calorie diet) (P=0.039 between study groups).
“synbiotic supplementation resulted in a significant reduction in leptin (P=0.003) and TNF-α (P=0.039) between the study groups”
Human trialbetween study groups, both groups on a low-calorie diet10 weeks
EXCLI journal
Synbiotics decrease TNF-alpha in humans (SMD = -0.36).
“whereas synbiotics reduced TNF-α (SMD = -0.36).”
Review
Nutrition journal
Lipopolysaccharide-binding protein
downin humans1
1 study
Lipopolysaccharide-binding protein
downin humans1
Synbiotics decrease lipopolysaccharide-binding protein in overweight or obese kidney transplant recipients on a calorie-restricted diet.
“However, the reduction of serum LBP concentration was significantly higher in the synbiotic group than in the placebo group (p = 0.03; ).”
Human trialin overweight or obese kidney transplant recipients on a calorie-restricted diet12 weeks
Renal failure
Synbiotics decrease lipopolysaccharide-binding protein in humans (p = 0.03).
“Serum LBP (p = 0.03), hs-CRP (p = 0.02), ICAM-1 (p = 0.04), and IL-6 (p = 0.02) showed significant reductions in the synbiotic group compared to the placebo group.”
Human trialcapsules12 weeks
Renal failure
VCAM-1
downin humans1
1 study
VCAM-1
downin humans1
Synbiotics decrease VCAM-1 in humans.
“As seen in Table, the mean serum VCAM-1 level decreased significantly in the synbiotic group, compared to the placebo group after adjusting for VCAM-1 baseline values (p < 0.001).”
Human trial4 monthsn = 96
Nutrition & diabetes
Synbiotics decrease VCAM-1 in humans (type 2 diabetes and high cardiovascular risk) (-85.70 ng/L (-150.14 to -21.26)).
“vascular cell adhesion molecule 1 (VCAM-1) [-85.70 ng/L (-150.14 to -21.26)]”
Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85
Nutrition & diabetes
LDL-C
downin humans1
1 study
LDL-C
downin humans1
Synbiotics decrease LDL-C in humans.
“Synbiotic supplements were better than placebo in decreasing the LDL-C after adjusting for LDL baseline values (p = 0.002).”
Human trial4 monthsn = 96
Nutrition & diabetes
Synbiotics decrease LDL-C in humans (type 2 diabetes and high cardiovascular risk) (-10.83 mg/dl (-14.78 to -6.88)).
“The mean serum Low-density-Lipoprotein (LDL-C) [-10.83 mg/dl (-14.78 to -6.88)], and total cholesterol [-11.78 mg/dl (-16.44 to -7.11)]”
Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85
Nutrition & diabetes
Fasting plasma glucose
downin humans1
1 study
Fasting plasma glucose
downin humans1
Synbiotics decrease fasting plasma glucose in humans.
“There was a significant difference between the synbiotic and placebo groups after adjusting for FPG baseline values and weight changes due to the treatment (p = 0.003).”
Human trial4 monthsn = 96
Nutrition & diabetes
Synbiotics decrease fasting plasma glucose in humans (type 2 diabetes and high cardiovascular risk) (-22.83 mg/dl (-31.30 to -14.36)).
“fasting plasma glucose (FPG) [-22.83 mg/dl (-31.30 to -14.36)], and homeostatic model assessment for insulin resistance (HOMA-IR.) [-1.31 (-1.75 to -0.86)] improved in the synbiotic group significantly”
Human trialtype 2 diabetes and high cardiovascular risk4 monthsn = 85
Nutrition & diabetes
Lipopolysaccharide
downin humans1
1 study
Lipopolysaccharide
downin humans1
Synbiotics decrease lipopolysaccharide in humans (70.35 ± 11.43 to 28.57 ± 8.84 pg/mL in stressed; 66.78 ± 13.73 to 16.01 ± 3.74 pg/mL in non-stressed).
“Synbiotics attenuated LPS level in both stressed participants (70.35 ± 11.43 to 28.57 ± 8.84 pg/mL, p < 0.001) and non-stressed participants (66.78 ± 13.73 to 16.01 ± 3.74 pg/mL, p = 0.002), whereas it promoted IgA elevation.”
Human trial12 weeksn = 32
Foods (Basel, Switzerland)
Synbiotics decrease lipopolysaccharide in humans.
“cortisol, and lipopolysaccharide (LPS) were reduced”
Human trial12 weeksn = 32
Foods (Basel, Switzerland)
Thai Stress Test negative scale score
downin humans1
1 study
Thai Stress Test negative scale score
downin humans1
Synbiotics decrease Thai Stress Test negative scale score in the stressed group (from 13.53 ± 1.20 at the baseline to 8.21 ± 1.33 at the 12th week).
“Although there was no significant change of stress status in the stressed group, the outcome was exhibited the decreasing negative scale scores of TST from 13.53 ± 1.20 at the baseline to 8.21 ± 1.33 at the 12th week; p = 0.001.”
Human trialin the stressed group12 weeks
Foods (Basel, Switzerland)
Synbiotics decrease Thai Stress Test negative scale score in humans (stressed participants) (p < 0.05).
“In the stressed group, the administration of synbiotics significantly (p < 0.05) reduced the negative scale scores of TST”
Human trialstressed participants12 weeksn = 32
Foods (Basel, Switzerland)
HDL cholesterol
no changein humans1
1 study
HDL cholesterol
no changein humans1
Synbiotics showed no clear effect on HDL cholesterol in humans (kidney transplant recipients with overweight or obesity).
“However, there were no significant changes in serum HDL-cholesterol and Lp(a) for either group throughout the study period.”
Human trialkidney transplant recipients with overweight or obesitycapsulesserumtwo capsules daily12 weeksn = 46
The British journal of nutrition
Total cholesterol
downin humans1
1 study
Total cholesterol
downin humans1
Synbiotics decrease total cholesterol in humans (kidney transplant recipients with overweight or obesity; compared with placebo) (effect size −0.75).
“The results indicated significant reductions in serum total cholesterol ( P = 0·022; effect size= −0·75)”
Human trialkidney transplant recipients with overweight or obesity; compared with placebocapsulesserumtwo capsules daily12 weeksn = 46
The British journal of nutrition
Fat-free mass
no changein humans1
1 study
Fat-free mass
no changein humans1
Synbiotics showed no clear effect on fat-free mass in humans (perimenopausal women with migraine and intestinal dysbiosis).
“with FFM remaining broadly stable”
Human trialperimenopausal women with migraine and intestinal dysbiosis6 monthsfemales
Preprints.orgPreprint
All 37Fewer
What is synbiotics linked with?
3Studies link synbiotics with 3 measures: gut microbiota composition, mortality and neurodegenerative disease.
Gut microbiota composition
mixedin reviews1
1 study
Gut microbiota composition
mixedin reviews1
Synbiotics are associated with gut microbiota composition.
“Prebiotics and probiotics have been shown to modulate the gut microbiota”
Review
Preprints.orgPreprint
Mortality
downin humans1
1 study
Mortality
downin humans1
Synbiotics are linked with a lower risk of mortality in humans.
“nondietary prebiotic and probiotic supplement intake was also associated with a reduced risk of mortality in an older US population”
Humans
Archives of gerontology and geriatrics
Neurodegenerative disease
downin reviews1
1 study
Neurodegenerative disease
downin reviews1
Synbiotics lower the risk of neurodegenerative disease.
“the risk of neurodegenerative diseases can be reduced by using probiotics, or preferably by combining probiotics and prebiotics, also known as synbiotics”
Review
Frontiers in bioscience (Elite edition)
Has synbiotics been tested in people?
0 of 3 about agingYes: 14 trials and 1 observational study in people have been published, and 3 trials are registered.
In trials
Phase 4Status unknown1 trial
Phase 2Status unknown1 trial
Gut microbiota
No phaseActive, not recruiting1 trial
Who is developing synbiotics?
1 company: Leeuwenhoek Laboratories.
- Companies
- Leeuwenhoek LaboratoriesPhase 2obesity
Trial sponsors
Company1 trialPhase 280 people
Company1 trial268 people
Funding
2 grants since 2024Japan Society for the Promotion of Science¥4.6MInnovative UK£186K
Superior synbiotics for healthy ageing
Innovative UKNcimb£186K2024–2026
Research on the effect of synbiotics on suppressing cancer sarcopenia
Japan Society for the Promotion of ScienceNara Medical University¥4.6M2024–2026
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary written from the findings.